Evaluation of potential respiratory stimulant. TO4. Period of performance: march 21, 2024 - march 20, 2025.
Ended Awarded Last action
- Contract number
- 75N95024F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $140,848
Award facts
- Opportunity
-
- 75N95024F00001 Solicitation number
- Contract value 100% obligated
- $140,848.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $140,848 |
About this award
This federal contract award is for the evaluation of a potential respiratory stimulant on behalf of the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). The award, with a ceiling value of $140,848.00, was issued to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The scope of work includes nonclinical animal studies to assess potential treatments for drug-induced respiratory depression and overdose toxicity, a major program area for NIDA. The period of performance is from March 21, 2024 to March 20, 2025, with a final completion date of April 28, 2025. This work is being conducted under a Delivery Order contract with a Cost Plus Fixed Fee pricing type. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N95024F00001?
75N95024F00001 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on March 21, 2024.
How much is contract 75N95024F00001 worth?
The government has obligated $140,848 on 75N95024F00001.
Is contract 75N95024F00001 an order under another contract?
Yes. 75N95024F00001 is a delivery order under 75N95022D00019, an indefinite delivery contract.
Was contract 75N95024F00001 competed?
The extent of competition for 75N95024F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award